Regeneron Reports Phase 3 EMPOWER-Cervical 1 Results for Libtayo in Cervical Cancer

Regeneron today announced results from the Phase 3 EMPOWER-Cervical 1 trial evaluating Libtayo (cemiplimab) versus investigator's choice of chemotherapy in patients with recurrent or metastatic cervical cancer who had progressed on first-line platinum-based chemotherapy. The trial met its primary endpoint, demonstrating a significant improvement in overall survival with Libtayo.